Etanercept biosimilar (Samsung Bioepis)

依那西普生物类似药（三星 Bioepis）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEtanercept biosimilar (Samsung Bioepis)
Drug Alias Name依那西普生物仿制药（三星 Bioepis）Etanercept-YKROetanercept biosimilarEticovoBenepali +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionTumor necrosis factor β inhibitorsTumor necrosis factor α inhibitors
TargetsTumor necrosis factor βTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Global Approved IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2016/01/13
Country/TerritoryUnited StatesPolandGermany +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSamsung Bioepis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBiogen IncMerck & Co IncSamsung Bioepis Nl Bv +[5] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisArthritis, Rheumatoid +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB01
Related LinksN/A